Sarepta enters $500M upfront license deal with Arrowhead for siRNA therapies; GC resigns

Sarepta Therapeutics, Inc.

$500M upfront cash to Arrowhead; up to $300M near-term payments; up to $180M per program development milestones, $700M per program sales milestones; tiered royalties up to low double digits.
Sarepta purchases 11.9M shares of Arrowhead for $325M in a private placement, with 180-day lock-up and standstill for up to 5 years.
Programs include clinical siRNA candidates for FSHD, DM1, ataxias, IPF, and pre-clinical for Huntington's; Sarepta can select six additional discovery targets.
Arrowhead leads initial development and manufacturing; Sarepta assumes responsibility at transition points and holds global commercialization rights.
EVP Chief General Counsel Ryan Brown resigns effective Nov 26; Cristin Rothfuss named successor as EVP General Counsel.

item 1.01 item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ryan Brown

Executive Vice President, Chief General Counsel

SRPT · Sarepta Therapeutics, Inc.

Effective: 2024-11-26
Successor: Cristin Rothfuss
Filed: November 26, 2024, 6:59 PM ET

Ryan Brown informed Sarepta of his resignation from his position as the Company’s Executive Vice President, Chief General Counsel, effective as of November 26, 2024.

Appointed

Cristin Rothfuss

Executive Vice President, General Counsel

SRPT · Sarepta Therapeutics, Inc.

Effective: 2024-11-26
Filed: November 26, 2024, 6:59 PM ET

Cristin Rothfuss, the Company’s Senior Vice President, Deputy General Counsel, will succeed Mr. Brown as the Company’s Executive Vice President, General Counsel.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ryan Brown resigned as Executive Vice President, Chief General Counsel at Sarepta Therapeutics, Inc..

Action: resigned
Role: Executive Vice President, Chief General Counsel

Exact text from the filing

Ryan Brown informed Sarepta of his resignation from his position as the Company’s Executive Vice President, Chief General Counsel, effective as of November 26, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Cristin Rothfuss was appointed as Executive Vice President, General Counsel at Sarepta Therapeutics, Inc..

Action: appointed
Role: Executive Vice President, General Counsel

Exact text from the filing

Cristin Rothfuss, the Company’s Senior Vice President, Deputy General Counsel, will succeed Mr. Brown as the Company’s Executive Vice President, General Counsel.

View on SEC.gov

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-265627

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.